Johnson & Johnson (JNJ) DEF 14A15 Mar 23Definitive proxyFinancial data

Company Profile

Cover

Cover	12 Months Ended
Cover	Jan. 01, 2023
Document Information [Line Items]
Document Type	DEF 14A
Amendment Flag	false
Entity Information [Line Items]
Entity Registrant Name	JOHNSON & JOHNSON
Entity Central Index Key	0000200406

Pay vs Performance Disclosure

Pay vs Performance Disclosure	12 Months Ended
Pay vs Performance Disclosure	Jan. 01, 2023 USD ($) $ / shares	Jan. 02, 2022 USD ($) $ / shares	Jan. 03, 2021 USD ($) $ / shares
Pay vs Performance Disclosure [Table]
Pay vs Performance [Table Text Block]	A B C D E F G H I J Value of Initial Fixed $100 Investment Based On: Year Summary Compensation Table Total for PEO Compensation Actually Paid to PEO Average Summary Compensation Table Total for non-PEO NEOs Average Compensation Actually Paid to non-PEO NEOs Total Shareholder Return Peer Group Total Shareholder Return Peer Group Total Shareholder Return Net Income ($millions) Annual Relative Total Shareholder Return 2022 $13,099,487 $18,910,984 $8,021,796 $11,882,576 $130.91 $146.65 $113.92 17,941 5.6 % 2021 26,741,959 39,418,762 12,498,029 16,589,485 123.54 135.21 140.40 20,878 (2.4) 2020 29,575,974 28,993,387 12,948,370 11,481,072 110.85 107.53 117.63 14,714 1.6
Named Executive Officers, Footnote [Text Block]	Column B includes the amounts reported in the Total column of the Summary Compensation Table for our CEO. Column D includes the average of the amounts reported in the Total column of the Summary Compensation Table for our named executive officers excluding our CEO. In the table below, we show which executives were included in columns B through E in 2020-2022. Executive Name PEO Non-PEO NEO 2020 2021 2022 2020 2021 2022 A. Gorsky X X J. Duato X X X J. Wolk X X X P. Stoffels X X J. Taubert X X X A. McEvoy X T. Mongon X
Peer Group Issuers, Footnote [Text Block]	Competitor Composite Peer Group Pharmaceuticals MedTech Consumer Health AbbVie Inc Alcon Beiersdorf AG Amgen Inc Boston Scientific Corp Colgate-Palmolive Co AstraZeneca PLC Cooper Cos Inc L'Oreal SA Bristol-Myers Squibb Co The Intuitive Surgical Procter & Gamble Co Eli Lilly & Co Medtronic Inc The Reckitt Benckiser GlaxoSmithKline PLC Smith & Nephew PLC Unilever Merck & Co Inc Stryker Corp Novartis AG Zimmer Holdings Inc Pfizer Inc Roche Holding AG Sanofi
PEO Total Compensation Amount	$ 13,099,487	$ 26,741,959	$ 29,575,974
PEO Actually Paid Compensation Amount	$ 18,910,984	39,418,762	28,993,387
Adjustment To PEO Compensation, Footnote [Text Block]	Year Year-End Fair Value of Equity Awards Granted During Applicable Year Change in Fair Value as of Year-End of Any Prior-Year Awards that Remain Unvested as of Year-End Change in Fair Value as of the Vesting Date of Any Prior -Year Awards that Vested During Applicable Year Pay Versus Performance Value of Equity Awards PEO 2022 $10,012,527 $4,005,011 $(420,254) $13,597,284 2021 21,784,640 7,510,917 2,928,188 32,223,745 2020 17,452,777 3,954,446 2,158,449 23,565,672 Average of Non-PEO NEOs 2022 7,204,994 2,486,599 (201,362) 9,490,231 2021 8,964,136 3,045,440 836,235 12,845,811 2020 7,143,024 1,311,996 599,228 9,054,248 Year Service Costs Attributable to the Applicable Year Prior Service Costs Introduced During the Applicable Year Pay Versus Performance Value of Pension Benefits PEO 2022 $474,001 $0 $474,001 2021 988,230 0 988,230 2020 948,152 (519,762) 428,390 Average of Other NEOs 2022 329,779 0 329,779 2021 575,029 0 575,029 2020 423,888 (533,939) (110,051)
Non-PEO NEO Average Total Compensation Amount	$ 8,021,796	12,498,029	12,948,370
Non-PEO NEO Average Compensation Actually Paid Amount	$ 11,882,576	16,589,485	11,481,072
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]	The following table shows adjustments made to total compensation for each year to determine the Compensation Actually Paid: Year Summary Compensation Table Total Minus Plus Minus Plus Equals Compensation Actually Paid PEO 2022 $13,099,487 $8,259,788 $13,597,284 $0 $474,001 $18,910,984 2021 26,741,959 19,859,172 32,223,745 676,000 988,230 39,418,762 2020 29,575,974 18,140,649 23,565,672 6,436,000 428,390 28,993,387 Average of Non-PEO NEOs 2022 8,021,796 5,943,730 9,490,231 15,500 329,779 11,882,576 2021 12,498,029 8,169,384 12,845,811 1,160,000 575,029 16,589,485 2020 12,948,370 7,411,495 9,054,248 3,000,000 (110,051) 11,481,072 Year Year-End Fair Value of Equity Awards Granted During Applicable Year Change in Fair Value as of Year-End of Any Prior-Year Awards that Remain Unvested as of Year-End Change in Fair Value as of the Vesting Date of Any Prior -Year Awards that Vested During Applicable Year Pay Versus Performance Value of Equity Awards PEO 2022 $10,012,527 $4,005,011 $(420,254) $13,597,284 2021 21,784,640 7,510,917 2,928,188 32,223,745 2020 17,452,777 3,954,446 2,158,449 23,565,672 Average of Non-PEO NEOs 2022 7,204,994 2,486,599 (201,362) 9,490,231 2021 8,964,136 3,045,440 836,235 12,845,811 2020 7,143,024 1,311,996 599,228 9,054,248 Year Service Costs Attributable to the Applicable Year Prior Service Costs Introduced During the Applicable Year Pay Versus Performance Value of Pension Benefits PEO 2022 $474,001 $0 $474,001 2021 988,230 0 988,230 2020 948,152 (519,762) 428,390 Average of Other NEOs 2022 329,779 0 329,779 2021 575,029 0 575,029 2020 423,888 (533,939) (110,051)
Compensation Actually Paid vs. Total Shareholder Return [Text Block]	The chart below compares the Compensation Actually Paid to our CEO and the average of our other NEOs with the Company’s cumulative TSR. As described on page 70, three-year TSR relative to our Competitor Composite Peers is one of our PSU performance measures. However, the Company’s cumulative TSR without a peer comparison is not one of the performance measures we use in our annual or long-term incentive plans. The Company’s cumulative TSR includes both our annual share price appreciation and the impact of reinvested dividends. Because most of our executives’ compensation is equity-based long-term incentives which vary in value with the Company’s price, our CAP is aligned with the annual share price appreciation component of TSR. Dividends confound the relationship because they are included in the cumulative TSR but are not included in CAP because we do not pay dividends on unvested equity awards.
Compensation Actually Paid vs. Net Income [Text Block]	The chart below compares the Compensation Actually Paid to our CEO and the average of our other NEOs with the Company’s net income. As described on pages 67 and 70, adjusted operational EPS is one of our annual incentive measures and three-year cumulative adjusted operational EPS is one of our PSU performance measures. These measures are compared to goals that we set at the beginning of each year for the annual incentives and at the beginning of each 3-year performance period for the PSUs. While annual net income impacts our adjusted operational EPS and three-year cumulative adjusted operational EPS, it is not one of the performance measures we use in our annual or long-term incentive plans. Therefore, any relationship of CAP with the Company’s annual net income would be indirect, at best, because it is not a performance measure in our compensation program and it is not compared to any goals.
Compensation Actually Paid vs. Company Selected Measure [Text Block]	The chart below compares the Compensation Actually Paid to our CEO and the average of our other NEOs with the Company’s annual relative TSR. Annual relative TSR directly impacts the three overlapping PSU performance cycles that are outstanding each year. Higher annual relative TSR increases the fair value of the outstanding PSUs and conversely lower annual relative TSR decreases the fair value of outstanding PSUs. Performance against our annual incentive goals, three-year cumulative adjusted operational EPS PSU goals, and changes in the fair value of long-term incentive awards granted each year confound the relationship of CAP and annual relative TSR because they are independent of annual relative TSR. Note: we use three-year relative TSR as a PSU performance measure. However, SEC guidance limits the measures to one-year periods. Annual Relative TSR TSR 2020 2021 2022 Johnson & Johnson 9.3 % 12.8 % 8.0 % Competitor Composite 7.7 15.2 2.4 One-Year Relative TSR 1.6 (2.4) 5.6 The TSR for each of the three business groups within the Competitor Composite Peer Group is weighted based on the Company’s sales mix for the prior year as shown in the table below. Competitor Composite Peer Group Weightings Business Group 2020 2021 2022 Pharmaceuticals 51.4 % 54.7 % 55.1 % MedTech 31.6 27.8 28.9 Consumer Health 16.9 17.5 16.0 Total 100.0 100.0 100.0
Total Shareholder Return Vs Peer Group [Text Block]	The chart below compares the Company's cumulative TSR over the three years presented in the table with the cumulative TSR of our two peer indices: the S&P Pharmaceuticals Index and the S&P Healthcare Equipment Index. We do not use the cumulative TSR of the S&P Pharmaceuticals Index or S&P Healthcare Equipment index as incentive measures for our NEOs. However, we do measure three-year relative TSR versus our Competitor Composite Peer Group as one of our PSU metrics, as described in greater detail in our PSU Goal Setting Process on page 70. So, the relationship of CAP with our three-year relative TSR versus our Competitor Composite Peer Group is direct for each of the overlapping PSU performance periods shown in the table.
Tabular List [Table Text Block]	Annual Incentive Long-Term Incentive l Operational Sales l Three-Year Cumulative Adjusted Operational EPS l Adjusted Operational EPS Growth l Three-Year TSR Compound Annual Growth Rate versus the Competitor Composite Peer Group l Free Cash Flow l Share Price l Share Price Appreciation
Total Shareholder Return Amount	$ 130.91	123.54	110.85
Peer Group Total Shareholder Return Amount	146.65	135.21	107.53
Net Income (Loss)	$ 17,941,000,000	$ 20,878,000,000	$ 14,714,000,000
Company Selected Measure Amount	0.056	(0.024)	0.016
Peer Group Total Shareholder Return Amount, Two \| $ / shares	$ 113.92	$ 140.40	$ 117.63
Measure [Axis]: 1
Pay vs Performance Disclosure [Table]
Measure Name	Operational Sales
Measure [Axis]: 2
Pay vs Performance Disclosure [Table]
Measure Name	Adjusted Operational EPS Growth
Measure [Axis]: 3
Pay vs Performance Disclosure [Table]
Measure Name	Free Cash Flow
Measure [Axis]: 4
Pay vs Performance Disclosure [Table]
Measure Name	Three-Year Cumulative Adjusted Operational EPS
Measure [Axis]: 5
Pay vs Performance Disclosure [Table]
Measure Name	Three-Year TSR Compound Annual Growth Rate versus the Competitor Composite Peer Group
Measure [Axis]: 6
Pay vs Performance Disclosure [Table]
Measure Name	Share Price
Measure [Axis]: 7
Pay vs Performance Disclosure [Table]
Measure Name	Share Price Appreciation
PEO [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	$ 474,001	$ 988,230	$ 428,390
PEO [Member] \| Exclusion of Equity Awards [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	8,259,788	19,859,172	18,140,649
PEO [Member] \| Equity Award Adjustments [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	13,597,284	32,223,745	23,565,672
PEO [Member] \| Exclusion of Change in Pension Benefit [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	0	676,000	6,436,000
PEO [Member] \| Inclusion of Pension Benefit [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	474,001	988,230	428,390
PEO [Member] \| Equity Awards Granted During the Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount, Equity Awards	10,012,527	21,784,640	17,452,777
PEO [Member] \| Equity Awards Granted in Prior Years, Unvested [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount, Equity Awards	4,005,011	7,510,917	3,954,446
PEO [Member] \| Equity Awards Granted in Prior Years, Vested [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount, Equity Awards	(420,254)	2,928,188	2,158,449
PEO [Member] \| Inclusion of Pension Service Costs [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	474,001	988,230	948,152
PEO [Member] \| Inclusion of Prior Year Pension Service Cost [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	0	0	(519,762)
Non-PEO NEO [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	329,779	575,029	(110,051)
Non-PEO NEO [Member] \| Exclusion of Equity Awards [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	5,943,730	8,169,384	7,411,495
Non-PEO NEO [Member] \| Equity Award Adjustments [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	9,490,231	12,845,811	9,054,248
Non-PEO NEO [Member] \| Exclusion of Change in Pension Benefit [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	15,500	1,160,000	3,000,000
Non-PEO NEO [Member] \| Inclusion of Pension Benefit [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	329,779	575,029	(110,051)
Non-PEO NEO [Member] \| Equity Awards Granted During the Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount, Equity Awards	7,204,994	8,964,136	7,143,024
Non-PEO NEO [Member] \| Equity Awards Granted in Prior Years, Unvested [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount, Equity Awards	2,486,599	3,045,440	1,311,996
Non-PEO NEO [Member] \| Equity Awards Granted in Prior Years, Vested [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount, Equity Awards	(201,362)	836,235	599,228
Non-PEO NEO [Member] \| Inclusion of Pension Service Costs [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	329,779	575,029	423,888
Non-PEO NEO [Member] \| Inclusion of Prior Year Pension Service Cost [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	$ 0	$ 0	$ (533,939)